A Phase 2 interventional study of BMS-986165 and Placebo for BMS-986165 in Psoriasis, sponsored by Bristol-Myers Squibb. Completed at 76 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-11-27.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing deucravacitinib in Psoriasis — 6 open to participants now, 6 under way, 4 of them phase 3. deucravacitinib · Psoriasis.
Among the 26 studies testing deucravacitinib in Psoriasis, this one is the 8th largest by enrollment, is the only one that started in 2016, is the only one in phase 2, and was the 1st registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 26 studies testing deucravacitinib in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Belgium and 13 more countries
Ages 12–17
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 22 more countries
Ages 40+
University of California, San Francisco · Sites in United States
Ages 18–75
Bristol-Myers Squibb · Sites in Argentina, Australia, Brazil and 10 more countries
Ages 4–18
Bristol-Myers Squibb
Ages 4–75
By country, each count listing its studies:
deucravacitinib: first FDA approval 2022 (SOTYKTU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 2 · Phase 3 10 · Phase 4 8
First in 2016; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 268 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 102 across the 26 interventional studies. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 26 have an industry lead sponsor. The 8 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
42 studies in Psoriasis by Bristol-Myers Squibb: 9 open now, 14 under way, 4 of them phase 3. Of 28 finished, 10 (36%) have results posted.
Among the 42 studies in Psoriasis by Bristol-Myers Squibb, this one is the 8th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2016, is one of 5 in phase 2, and was the 7th registered.
Bristol-Myers Squibb’s Psoriasis studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing deucravacitinib in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 42 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Specified dose of BMS-986165 on specified days.
Drug: BMS-986165
Specified dose of BMS-986165 on specified days.
Drug: BMS-986165
Specified dose of BMS-986165 on specified days.
Drug: BMS-986165
Specified dose of BMS-986165 on specified days.
Drug: BMS-986165
Specified dose of BMS-986165 on specified days.
Drug: BMS-986165
Specified dose of Placebo for BMS-986165 on specified days.
Drug: Placebo for BMS-986165
The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Day 85 (Week 12)
Psoriasis Area and Severity Index (PASI) 75 response: patients who achieved ≥ 75% improvement (reduction) in PASI score compared to baseline were defined as PASI 75 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.
Time frame: Day 1 to Day 85
Number of Participants With Adverse Events
The safety and tolerability of BMS-986195 as assessed by the number of subjects with adverse events (AEs); number of subjects with serious adverse events (SAEs); number of subjects with adverse events leading to discontinuation
Time frame: Day 1 to day 115
Percentage of Participants on Day 85 With PASI-50, PASI-90, PASI-100.
Percentage of patients achieving Psoriasis Area and Severity Index (PASI) 50, PASI 90 and PASI 100 responses on Day 85. PASI 50 response: patients who achieved ≥ 50% improvement (reduction) in PASI score compared to baseline were defined as PASI 50 responders. PASI 90 response: patients who achieved ≥ 90% improvement (reduction) in PASI score compared to baseline were defined as PASI 90 responders. PASI 100 response: patients who achieved ≥ 100% improvement (reduction) in PASI score compared to baseline were defined as PASI 100 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.
Time frame: Day 1 to Day 85
Percentage of Participants on Day 85 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate).
Percentage of participants achieving a clear (0) or almost clear (1) status on the Static Physician Global Assessment (sPGA) on Day 85. This index evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The assessment was scored on a scale of 0 to 5, where 0 = clear, with no evidence of plaque elevation, erythema, or scale, and 5 = severe induration, erythema, and scaling.
Time frame: Day 1 to Day 85
Change From Baseline in DLQI Scores on Day 85
The DLQI is a participant reported quality of life index which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a scale of 0 to 3 by a tick box: "not at all", "a little", "a lot", or "very much". The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum impairment)
Time frame: Day 1 to Day 85
Change From Baseline in BSA on Day 85
Measurement of psoriasis body surface area (BSA) involvement is estimated using the handprint method with the size of a patient's handprint representing \~1% of body surface area involved.The total BSA = 100% with breakdown by body region as follows: head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), trunk including axillae and groin = 30% (30 handprints), lower extremities including buttocks = 40% (40 handprints). A decrease from Baseline indicates improvement. Change from Baseline was calculated as Baseline score - Day 85 score; a positive change from Baseline therefore indicates improvement.
Time frame: Day 1 to Day 85
Trough Observed Plasma Concentration of BMS-986165 (Ctrough)
Pharmacokinetics of BMS-986165 were derived from plasma concentration versus time data. Ctrough= Trough observed plasma concentration
Time frame: Days 8, 15, 29, 57, 85
| Milestone | Placebo | BMS-986165 3MG QOD | BMS-986165 3MG QD | BMS-986165 3MG BID | BMS-986165 6MG BID | BMS-986165 12MG QD |
|---|---|---|---|---|---|---|
| Started | 45 | 44 | 44 | 45 | 45 | 44 |
| Completed | 31 | 34 | 36 | 42 | 39 | 42 |
| Not completed | 14 | 10 | 8 | 3 | 6 | 2 |
| Withdrew: Reason not provided by investigator | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Poor/non-compliance | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 5 | 4 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 1 | 2 | 0 |
| Withdrew: Subject request to discontinue treatment | 4 | 3 | 3 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 2 | 1 | 2 | 1 | 3 | 1 |
Psoriasis Area and Severity Index (PASI) 75 response: patients who achieved ≥ 75% improvement (reduction) in PASI score compared to baseline were defined as PASI 75 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.
| Percentage | Placebo | BMS-986165 3MG QOD | BMS-986165 3MG QD | BMS-986165 3MG BID | BMS-986165 6MG BID | BMS-986165 12MG QD |
|---|---|---|---|---|---|---|
| The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Day 85 (Week 12) | 6.7 (1.4 to 18.3) | 9.1 (2.5 to 21.7) | 38.6 (24.4 to 54.5) | 68.9 (53.4 to 81.8) | 66.7 (51.0 to 80.0) | 75.0 (59.7 to 86.8) |
Percentage of patients achieving Psoriasis Area and Severity Index (PASI) 50, PASI 90 and PASI 100 responses on Day 85. PASI 50 response: patients who achieved ≥ 50% improvement (reduction) in PASI score compared to baseline were defined as PASI 50 responders. PASI 90 response: patients who achieved ≥ 90% improvement (reduction) in PASI score compared to baseline were defined as PASI 90 responders. PASI 100 response: patients who achieved ≥ 100% improvement (reduction) in PASI score compared to baseline were defined as PASI 100 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.
| Percentage | Placebo | BMS-986165 3MG QOD | BMS-986165 3MG QD | BMS-986165 3MG BID | BMS-986165 6MG BID | BMS-986165 12MG QD |
|---|---|---|---|---|---|---|
| % of participants with PASI-50 at Day 85 | 31.1 (18.2 to 46.6) | 43.2 (28.3 to 59.0) | 68.2 (52.4 to 81.4) | 91.1 (78.8 to 97.5) | 77.8 (62.9 to 88.8) | 88.6 (75.4 to 96.2) |
| % of participants with PASI-90 at Day 85 | 2.2 (0.1 to 11.8) | 6.8 (1.4 to 18.7) | 15.9 (6.6 to 30.1) | 44.4 (29.6 to 60.0) | 44.4 (29.6 to 60.0) | 43.2 (28.3 to 59.0) |
| % of participants with PASI-100 at Day 85 | 0 (0.0 to 7.9) | 2.3 (0.1 to 12.0) | 0 (0.0 to 8.0) | 8.9 (2.5 to 21.2) | 17.8 (8.0 to 32.1) | 25.0 (13.2 to 40.3) |
Percentage of participants achieving a clear (0) or almost clear (1) status on the Static Physician Global Assessment (sPGA) on Day 85. This index evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The assessment was scored on a scale of 0 to 5, where 0 = clear, with no evidence of plaque elevation, erythema, or scale, and 5 = severe induration, erythema, and scaling.
| Percentage | Placebo | BMS-986165 3MG QOD | BMS-986165 3MG QD | BMS-986165 3MG BID | BMS-986165 6MG BID | BMS-986165 12MG QD |
|---|---|---|---|---|---|---|
| Percentage of Participants on Day 85 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate). | 6.7 (1.4 to 18.3) | 20.5 (9.8 to 35.3) | 38.6 (24.4 to 54.5) | 75.6 (60.5 to 87.1) | 64.4 (48.8 to 78.1) | 75.0 (59.7 to 86.8) |
The DLQI is a participant reported quality of life index which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a scale of 0 to 3 by a tick box: "not at all", "a little", "a lot", or "very much". The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum impairment)
| Score | Placebo | BMS-986165 3MG QOD | BMS-986165 3MG QD | BMS-986165 3MG BID | BMS-986165 6MG BID | BMS-986165 12MG QD |
|---|---|---|---|---|---|---|
| Change From Baseline in DLQI Scores on Day 85 | -2.85 (-4.33 to -1.37) | -3.76 (-5.15 to -2.38) | -6.07 (-8.07 to -4.08) | -9.67 (-11.42 to -7.93) | -8.38 (-10.72 to -6.03) | -10.16 (-12.27 to -8.06) |
Measurement of psoriasis body surface area (BSA) involvement is estimated using the handprint method with the size of a patient's handprint representing \~1% of body surface area involved.The total BSA = 100% with breakdown by body region as follows: head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), trunk including axillae and groin = 30% (30 handprints), lower extremities including buttocks = 40% (40 handprints). A decrease from Baseline indicates improvement. Change from Baseline was calculated as Baseline score - Day 85 score; a positive change from Baseline therefore indicates improvement.
| Percentage | Placebo | BMS-986165 3MG QOD | BMS-986165 3MG QD | BMS-986165 3MG BID | BMS-986165 6MG BID | BMS-986165 12MG QD |
|---|---|---|---|---|---|---|
| Change From Baseline in BSA on Day 85 | -7.71 (-11.88 to -3.54) | -5.50 (-8.17 to -2.83) | -12.59 (-18.28 to -6.89) | -18.60 (-23.69 to -13.52) | -17.23 (-20.85 to -13.60) | -15.16 (-18.64 to -11.69) |
Pharmacokinetics of BMS-986165 were derived from plasma concentration versus time data. Ctrough= Trough observed plasma concentration
| ng/mL | BMS-986165 3MG QOD | BMS-986165 3MG QD | BMS-986165 3MG BID | BMS-986165 6MG BID | BMS-986165 12MG QD |
|---|---|---|---|---|---|
| Trough Observed Plasma Concentration of BMS-986165 (Ctrough) | 2.024 ± 3.7061 | 3.145 ± 3.1588 | 14.819 ± 9.1410 | 26.257 ± 14.6483 | 17.824 ± 22.7536 |
The safety and tolerability of BMS-986195 as assessed by the number of subjects with adverse events (AEs); number of subjects with serious adverse events (SAEs); number of subjects with adverse events leading to discontinuation
| Participants | Placebo | BMS-986165 3MG QOD | BMS-986165 3MG QD | BMS-986165 3MG BID | BMS-986165 6MG BID | BMS-986165 12MG QD |
|---|---|---|---|---|---|---|
| No. of participants with SAEs | 1 | 1 | 1 | 1 | 0 | 0 |
| No. of participants with AEs | 24 | 26 | 25 | 29 | 36 | 34 |
| No. of participants discontinued due to AEs | 2 | 1 | 2 | 1 | 3 | 1 |
Collected over 20 weeks (assessed up to November 16, 2017). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/45 (0%) | 1/45 (2.2%) | 13/45 (28.9%) |
| BMS-986165 3mg QOD | 0/44 (0%) | 1/44 (2.3%) | 14/44 (31.8%) |
| BMS-986165 3mg QD | 0/44 (0%) | 1/44 (2.3%) | 18/44 (40.9%) |
| BMS-986165 3mg BID | 0/45 (0%) | 1/45 (2.2%) | 15/45 (33.3%) |
| BMS-986165 6mg BID | 0/45 (0%) | 0/45 (0%) | 25/45 (55.6%) |
| BMS-986165 12mg QD | 0/44 (0%) | 0/44 (0%) | 19/44 (43.2%) |
| Event | Placebo | BMS-986165 3mg QOD | BMS-986165 3mg QD | BMS-986165 3mg BID | BMS-986165 6mg BID | BMS-986165 12mg QD |
|---|---|---|---|---|---|---|
| Gastroenteritis rotavirusInfections and infestations | 0/45 | 1/44 | 0/44 | 0/45 | 0/45 | 0/44 |
| Eye injuryInjury, poisoning and procedural complications | 0/45 | 0/44 | 1/44 | 0/45 | 0/45 | 0/44 |
| Haemorrhagic anaemiaBlood and lymphatic system disorders | 1/45 | 0/44 | 0/44 | 0/45 | 0/45 | 0/44 |
| Haemorrhoidal haemorrhageGastrointestinal disorders | 1/45 | 0/44 | 0/44 | 0/45 | 0/45 | 0/44 |
| DizzinessNervous system disorders | 0/45 | 0/44 | 0/44 | 1/45 | 0/45 | 0/44 |
| Event | Placebo | BMS-986165 3mg QOD | BMS-986165 3mg QD | BMS-986165 3mg BID | BMS-986165 6mg BID | BMS-986165 12mg QD |
|---|---|---|---|---|---|---|
| Blood creatine phosphokinase increasedInvestigations | 1/45 | 0/44 | 1/44 | 0/45 | 4/45 | 7/44 |
| NasopharyngitisInfections and infestations | 2/45 | 1/44 | 5/44 | 5/45 | 7/45 | 3/44 |
| DiarrhoeaGastrointestinal disorders | 2/45 | 1/44 | 1/44 | 2/45 | 2/45 | 4/44 |
| NauseaGastrointestinal disorders | 2/45 | 4/44 | 0/44 | 1/45 | 1/45 | 2/44 |
| HeadacheNervous system disorders | 2/45 | 4/44 | 4/44 | 3/45 | 3/45 | 2/44 |
| AcneSkin and subcutaneous tissue disorders | 0/45 | 1/44 | 0/44 | 1/45 | 2/45 | 4/44 |
| Upper respiratory tract infectionInfections and infestations | 1/45 | 2/44 | 3/44 | 1/45 | 4/45 | 1/44 |
| Blood immunoglobulin e increasedInvestigations | 1/45 | 3/44 | 2/44 | 0/45 | 2/45 | 3/44 |
| PsoriasisSkin and subcutaneous tissue disorders | 2/45 | 1/44 | 3/44 | 2/45 | 0/45 | 0/44 |
| Aphthous ulcerGastrointestinal disorders | 0/45 | 0/44 | 0/44 | 3/45 | 0/45 | 1/44 |
| Age, Continuous(Years) | Placebo | BMS-986165 3MG QOD | BMS-986165 3MG QD | BMS-986165 3MG BID | BMS-986165 6MG BID | BMS-986165 12MG QD | Total |
|---|---|---|---|---|---|---|---|
| Mean | 46.4 ± 11.93 | 41.0 ± 11.8 | 45.0 ± 13.77 | 45.6 ± 15.10 | 42.8 ± 12.90 | 46.6 ± 11.62 | 44.6 ± 12.96 |
| Sex: Female, Male(Participants) | Placebo | BMS-986165 3MG QOD | BMS-986165 3MG QD | BMS-986165 3MG BID | BMS-986165 6MG BID | BMS-986165 12MG QD | Total |
|---|---|---|---|---|---|---|---|
| Female | 8 | 8 | 14 | 19 | 10 | 14 | 73 |
| Male | 37 | 36 | 30 | 26 | 35 | 30 | 194 |
| Race (NIH/OMB)(Participants) | Placebo | BMS-986165 3MG QOD | BMS-986165 3MG QD | BMS-986165 3MG BID | BMS-986165 6MG BID | BMS-986165 12MG QD | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 | 1 | 3 |
| Asian | 5 | 6 | 5 | 5 | 9 | 6 | 36 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| White | 40 | 35 | 39 | 39 | 35 | 37 | 225 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Nov 2017, 12 months.
Results were first posted in Nov 2020, 3 years after primary completion. A results delay was requested in Nov 2018.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 12 months is close to that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib